Navigation Links
YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
Date:12/12/2008

ain partnership revenues.

About YM BioSciences

YM BioSciences Inc. is a company that identifies, develops and commercializes differentiated products principally in the area of oncology for patients worldwide. The Company is developing nimotuzumab, a humanized monoclonal antibody, and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. Nimotuzumab is in development targeting multiple tumour types in combination with radiation, chemoradiation and chemotherapy. The drug, which is approved for marketing in a number of countries, is significantly differentiated from all other currently marketed EGFR-targeting agents because of a remarkably benign side-effect profile. In more than 3,000 patients treated worldwide, to date, no Grade III/IV rash or radiation dermatitis has been reported and reports of any of the other side-effects that are typical of EGFR-targeting molecules have been rare. AeroLEF(R) is in development for the treatment of moderate to severe pain, including cancer pain. The product completed a randomized trial in 2007 and is being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual repo
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
2. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
3. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
4. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
5. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
6. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
7. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
8. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
9. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
10. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- AVACEN Medical announced today that its AVACEN 100 ... by the U.S. Food and Drug Administration. This clearance ... Internet for: the temporary relief of joint pain ... sprains . Logo - http://photos.prnewswire.com/prnh/20141021/153513 ... a sophisticated medical device incorporating over 3,000 firmware instructions ...
(Date:10/22/2014)...   BioNano Genomics , the genome mapping ... to purchase an Irys™ System . Among them ... (NCI), NIH Intramural Sequencing Center (NISC) and Genoscope (The ... comprehensive view of a genome was a major ... deliver the scalability or reliability to detect and ...
(Date:10/22/2014)... , Oct. 22, 2014 InVivo Therapeutics ... MA is revolutionizing spinal cord injury (SCI) ... been shown to outperform in tissue regrowth in the ... scaffold.  Made from an FDA approved polymer, the scaffold ... it harmless to the human body. NVIV has recently ...
Breaking Medicine Technology:AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... Oct. 8 Pioneer Surgical Technology, Inc. and SpineSmith, ... Pioneer Surgical will acquire exclusive rights to manufacture and ... the agreement, Pioneer Surgical will become the manufacturer of ... sales network, while adding SpineSmith as a distributor.  "We ...
... Md., Oct. 8 Abbott Laboratories has agreed ... from the U.S. market because of clinical trial ... and stroke, the U.S. Food and Drug Administration ... ) (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) ...
Cached Medicine Technology:Pioneer® Surgical Technology, Inc. Announces Agreement to Acquire Exclusive Access to the Cequence™ Cervical Plate System From SpineSmith, LP 2Abbott Laboratories Agrees to Withdraw Its Obesity Drug Meridia 2
(Date:10/22/2014)... 22, 2014 On October 22, CBS ... featuring skin diseases both fictional and real. The ... nonprofit organization committed to advocacy and philanthropy in the ... take the opportunity to impart truth and clarity about ... There are many misconceptions about Morgellons Disease ...
(Date:10/22/2014)... Amy Norton HealthDay ... Headlines remain riveted on the three Ebola cases in Dallas. ... bigger health threat to Americans. President Barack Obama on ... to the virus, which has infected two Dallas nurses who ... month at Texas Health Presbyterian Hospital. But the U.S. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Hay House is ... Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written by ... Yoga & Recovery. This book is meant to help ... a life of recovery. , Recovery 2.0 is not ... Steps; Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... 22, 2014 Healthcare professionals who ... continuing education at home or on-the-go via laptops, ... 20 brand new, premium Seminar-on-Demand CE courses. The ... over 2,000 hours of CE course ... educational experience. With such a diverse library, there’s ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2
... so that,s what she pursued as a career. But she always ... some cardiologists at a party, she started talking with them about ... we could provide them with a fluid dynamics and mechanics point ... stent grafts they use in their procedures," she says. Stents ...
... sledding is a popular winter pastime, it can unfortunately ... the Center for Injury Research and Policy of The ... 1997-2007, an estimated 229,023 children and adolescents younger than ... for sledding-related injuries an average of more than ...
... found that while colon cancer rates have remained steady over ... 40, rectal cancer rates are increasing in this population across ... Cancer , a peer-reviewed journal of the American Cancer Society, ... rectal cancer in young individuals who show potential signs of ...
... 2010) -- A signaling protein released during rheumatoid arthritis ... impairment of mice bred to develop symptoms of the ... South Florida reports. Researchers found that the protein, ... attack and remove Alzheimer,s amyloid deposits in the brain. ...
... the nation,s largest general hospitals appeared to have a ... (RTAT), improving patient care, according to a study in ... Roentgenology ( www.ajronline.org ). One increasingly ... and Medicare Services and by third-party payers, attempts to ...
... the medical community has already accepted that colorectal cancer ... have found that computed tomography colonography (CTC or virtual ... yield of identifying significant early extracolonic (outside the colon) ... in the September issue of the American Journal of ...
Cached Medicine News:Health News:Math from the heart: Simulating stent design and coating 2Health News:Math from the heart: Simulating stent design and coating 3Health News:New study: More than 20,000 sledding injuries each year 2Health News:Rectal cancer rates are rising in young individuals 2Health News:Rheumatoid arthritis signaling protein reverses Alzheimer's disease in mouse model 2Health News:Rheumatoid arthritis signaling protein reverses Alzheimer's disease in mouse model 3Health News:Pay-for-performance programs improve radiology report turnaround times, study suggests 2
... special order products are offered as 1-piece ... lengths. The modular instruments may be customized ... such as ratchets, insulation and flush ports. ... stock. Customer specifications may affect delivery times. ...
... The Featured Products are ... Mediflex and are offered ... in regular or extra ... equipped with insulation, flush ...
... The Featured Products are ... Mediflex and are offered ... in regular or extra ... equipped with insulation, flush ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: